SCHEMBL9323398

SCHEMBL9323398

C[C@H](CCCO)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 10/20 0.74
▸ NR1H4 Q96RI1 3/20 0.74
▸ SLC10A2 Q12908 2/20 0.74
▸ TBXA2R P21731 1/20 0.74
▸ PDE3A Q14432 1/20 0.74
▸ MAPT P10636 3/20 0.71
▸ MAPK1 P28482 3/20 0.71
▸ MEN1 O00255 1/20 0.71
▸ KMT2A Q03164 1/20 0.71
▸ USP2 O75604 1/20 0.71
▸ LMNA P02545 1/20 0.71
▸ ABCC4 O15439 1/20 0.62
▸ CYP8B1 Q9UNU6 1/20 0.61
▸ OSBP P22059 1/20 0.60
▸ OSBP2 Q969R2 1/20 0.60
▸ ST6GAL1 P15907 1/20 0.58
▸ CA1 P00915 1/20 0.57
▸ CA2 P00918 1/20 0.57
▸ TP53 P04637 2/20 0.56
▸ CASP7 P55210 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16226390 1.00 GPBAR1 (0.74) GPBAR1NR1H4SLC10A2TBXA2RPDE3A
SCHEMBL16226649 1.00 GPBAR1 (0.74) GPBAR1NR1H4SLC10A2TBXA2RPDE3A
SCHEMBL16227156 0.94 GPBAR1 (0.77) GPBAR1NR1H4SLC10A2TBXA2RPDE3A
SCHEMBL16226417 0.94 GPBAR1 (0.77) GPBAR1NR1H4SLC10A2TBXA2RPDE3A
SCHEMBL19519612 0.92 GPBAR1 (0.74) GPBAR1NR1H4SLC10A2TBXA2RPDE3A
SCHEMBL16226880 0.92 GPBAR1 (0.74) GPBAR1NR1H4SLC10A2TBXA2RPDE3A
SCHEMBL17806641 0.92 GPBAR1 (0.74) GPBAR1NR1H4SLC10A2TBXA2RPDE3A
SCHEMBL6560685 0.92 GPBAR1 (0.74) GPBAR1NR1H4SLC10A2TBXA2RPDE3A
SCHEMBL15185968 0.92 GPBAR1 (0.74) GPBAR1NR1H4SLC10A2TBXA2RPDE3A
SCHEMBL12290838 0.92 GPBAR1 (0.74) GPBAR1NR1H4SLC10A2TBXA2RPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10723672-B2 Normal alpha olefin synthesis using dehydroformylation or dehydroxymethylation CHERVON PHILLIPS CHEMICAL COMPANY LP (US) 2020-07-28 — — US disclosed
US-20190263729-A1 Normal Alpha Olefin Synthesis Using Dehydroformylation or Dehydroxymethylation THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-08-29 — — US disclosed
US-20140335050-A1 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER THE GENERAL HOSPITAL CORPORATION (US) 2014-11-13 — — US disclosed
US-5304551-A Administering topically to treat ringworm or athlets foot BRITISH TECHNOLOGY GROUP LIMITED (GB) 1994-04-19 — — US disclosed
EP-0527832-A1 ANTI-FUNGAL BILE ACID DERIVATIVES LOUGHBOROUGH UNIVERSITY OF TECHNOLOGY (GB) 1993-02-24 — — EP disclosed
WO-1991016898-A1 ANTI-FUNGAL BILE ACID DERIVATIVES BRITISH TECHNOLOGY GROUP LTD (GB) 1991-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140335050-A1 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER IL2RA, CD74, IL2 GPBAR1 77/4885NR1H4 131/4885SLC10A2 3818/4885
US-10723672-B2 Normal alpha olefin synthesis using dehydroformylation or dehydroxymethylation ADH1A, ADH1C, DHPS GPBAR1 1306/4885NR1H4 1287/4885SLC10A2 2741/4885
US-20190263729-A1 Normal Alpha Olefin Synthesis Using Dehydroformylation or Dehydroxymethylation ADH1A, ADH1C, DHPS GPBAR1 1306/4885NR1H4 1287/4885SLC10A2 2741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback